fda glp 1 green list 'green list' flagging illegal GLP-1RA compounders is long overdue The GLP-1 shortage is real.

Safety considerations for GLP-1 receptor agonist use in post-bariatric surgery patients require careful attention, as this population may have unique vulnerabilities and altered pharmacokinetics compared to patients without surgical history

The drug pipelines have diversified

the data from individual studies did not reveal any statistically significant differences between GLP-1RAs and placebo

Vithalkar MP, Pradhan S, Sandra KS, Bharath HB, Nayak Y (2025) Modulating NLRP3 inflammasomes in idiopathic pulmonary fibrosis: a comprehensive review on flavonoid-based interventions

CAN is characterized by damage to the nerve fibers that innervate the heart and blood vessels, leading to reduced heart rate variability (variability in the time interval between heartbeats) and increased risk of mortality (80)

Haase, C